A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1
- Conditions
- Relapsed/Refractory B-cell MalignanciesMedDRA version: 21.1Level: LLTClassification code: 10068919Term: B-cell chronic lymphocytic leukemia Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10003908Term: B-cell small lymphocytic lymphoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10062113Term: Splenic marginal zone lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10076596Term: Marginal zone lymphoma Class: 100000004864MedDRA version: 24.0Level: LLTClassification code: 10080214Term: Follicular B-cell non-Hodgkin´s lymphoma unclassifiable Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10036685Term: Primary central nervous system lymphoma Class: 10029104Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-510541-25-00
- Lead Sponsor
- urix Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 292
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method